润都股份(002923.SZ)：苯磺顺阿曲库铵获化学原料药上市申请批准

Core Viewpoint - Rundu Pharmaceutical's subsidiary has received approval for a new drug, which expands its product offerings in the anesthetic and critical care market [1] Group 1: Company Developments - Rundu Pharmaceutical's subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd., has been granted a marketing approval notice for Benzylsuccinate Atracurium by the National Medical Products Administration [1] - The approved drug is indicated for use in adults and children aged one month and older for surgical procedures and other therapeutic interventions [1] - The drug can be utilized as an adjunct to general anesthesia or for sedation in the ICU to facilitate tracheal intubation and mechanical ventilation [1]